Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
FEMY 
Femasys Inc (FEMY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: FEMY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.25
1 Year Target Price $6.25
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 29.17% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.74M USD | Price to earnings Ratio - | 1Y Target Price 6.25 |
Price to earnings Ratio - | 1Y Target Price 6.25 | ||
Volume (30-day avg) 4 | Beta -2.58 | 52 Weeks Range 0.31 - 1.80 | Updated Date 08/29/2025 |
52 Weeks Range 0.31 - 1.80 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.86 |
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.16 | Actual -0.16 |
Profitability
Profit Margin - | Operating Margin (TTM) -941.09% |
Management Effectiveness
Return on Assets (TTM) -70.3% | Return on Equity (TTM) -329.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 16253880 | Price to Sales(TTM) 6.22 |
Enterprise Value 16253880 | Price to Sales(TTM) 6.22 | ||
Enterprise Value to Revenue 8.61 | Enterprise Value to EBITDA 0.24 | Shares Outstanding 32575400 | Shares Floating 27743171 |
Shares Outstanding 32575400 | Shares Floating 27743171 | ||
Percent Insiders 14.77 | Percent Institutions 15.6 |
Upturn AI SWOT
Femasys Inc
Company Overview
History and Background
Femasys Inc. is a biomedical company focused on developing innovative solutions in women's healthcare, particularly permanent contraception. Founded in 2004, it has focused on non-surgical options to meet the growing demand in women's contraception and infertility market.
Core Business Areas
- Contraception: Femasys' primary focus is on permanent contraception solutions for women, seeking to provide alternatives to surgical procedures like tubal ligations.
- Infertility: Development of diagnostic technologies and potential therapeutic solutions aimed at improving infertility outcomes for women.
Leadership and Structure
The company has a CEO and a leadership team overseeing various departments, including research and development, clinical affairs, and commercialization. The Board of Directors provides strategic oversight and guidance.
Top Products and Market Share
Key Offerings
- FemBloc: FemBloc is the primary product, a non-surgical permanent birth control method. It aims to compete with traditional surgical sterilization procedures. Market share data is limited due to its current stage of commercialization but early adoption is promising in limited rollouts. Competitors include surgical sterilization (tubal ligation), IUDs, and hormonal birth control. Revenue data is not broken down product wise.
Market Dynamics
Industry Overview
The women's healthcare market is experiencing growth, driven by the increasing demand for minimally invasive procedures, growing awareness of contraception options, and advancements in reproductive technologies.
Positioning
Femasys is positioned as a disruptor in the permanent contraception market, offering a non-surgical alternative to traditional sterilization procedures.
Total Addressable Market (TAM)
The total market for permanent contraception is estimated to be in the billions of dollars globally. Femasys aims to capture a significant portion of this market with its non-surgical approach.
Upturn SWOT Analysis
Strengths
- Non-surgical permanent contraception solution
- Potential for faster recovery and reduced risks compared to surgery
- Novel approach to a well-established market
Weaknesses
- Limited commercialization and market penetration
- Reliance on a single primary product (FemBloc)
- Need for extensive clinical data to support efficacy and safety
Opportunities
- Expanding market for minimally invasive procedures
- Growing demand for non-surgical contraception options
- Partnerships with healthcare providers and organizations
Threats
- Competition from established contraception methods
- Regulatory hurdles and approval processes
- Potential for adverse events or lack of efficacy
Competitors and Market Share
Key Competitors
- BDX
- BAYZF
- MNKD
Competitive Landscape
Femasys' competitive advantage lies in its non-surgical approach to permanent contraception. However, they face competition from established pharmaceutical companies, medical device manufacturers, and other contraception providers.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by funding rounds and clinical trial progress. Revenue growth is dependent on FemBloc's successful commercial launch.
Future Projections: Future growth is projected to be driven by increased adoption of FemBloc, expansion into new markets, and potential development of additional women's healthcare products.
Recent Initiatives: Recent initiatives include expanding their commercial team and the launch of pivotal clinical studies in key markets, increasing marketing efforts, and forming strategic partnerships.
Summary
Femasys Inc. is a high-risk, high-reward investment due to its innovative non-surgical contraception approach. Its success hinges on the commercial viability and market acceptance of FemBloc. The company needs to carefully manage its cash flow and navigate regulatory hurdles. Current financial health is weak but future growth potential in FemBloc sales may change this. Significant improvements in revenue will be required to improve the fundamental analysis.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Investor Relations
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share estimates are based on available data and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Femasys Inc
Exchange NASDAQ | Headquaters Suwanee, GA, United States | ||
IPO Launch date 2021-06-18 | Founder, President, CEO & Director Ms. Kathy Lee-Sepsick M.B.A. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 69 | Website https://www.femasys.com |
Full time employees 69 | Website https://www.femasys.com | ||
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-generating device for fallopian tube diagnosis. It also develops FemBloc, a non-surgical permanent birth control solution. The company offers its products to reproductive endocrinologists, gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.